Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

A 36-week screening strategy safely reduces pre-eclampsia at term

8

Dec 2025

A 36-week screening strategy safely reduces pre-eclampsia at term

Screening pregnant women at 36 weeks using a validated risk model and offering risk-stratified planned early-term birth reduced the incidence of term pre-eclampsia by about 30 percent without increasing maternal or neonatal complications. The randomised PREVENT-PE trial demonstrates that a personalised timing-of-birth strategy can prevent term pre-eclampsia where no effective medical prevention currently exists.

Early RSV infection turns maternal allergy into a powerful driver of childhood asthma

8

Dec 2025

Early RSV infection turns maternal allergy into a powerful driver of childhood asthma

Early-life RSV infection and parental allergy interact to substantially increase childhood asthma risk, supported by population data from more than 1.5 million children and mechanistic mouse experiments. The study shows that viral infection reprograms neonatal immune responses by altering how maternally transferred allergen-specific antibodies are handled, driving long-term allergic airway disease.

Laughing gas shows fast antidepressant effects in early clinical trials

8

Dec 2025

Laughing gas shows fast antidepressant effects in early clinical trials

A systematic review and meta-analysis in eBioMedicine shows that nitrous oxide can rapidly reduce depressive symptoms within hours, particularly at higher doses, but effects are short-lived after single treatments. Repeated dosing appears to extend and strengthen antidepressant benefits, although the current evidence is based on small, early-phase trials with limited long-term safety data.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.